The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Eli Lilly continues to reinvest heavily in its GLP-1 portfolio, signaling major shifts in availability, competition, and pricing. For patients on or considering tirzepatide, these moves have real implications for cost and access. Here's what you need to know.
Millions of people on GLP-1 medications like Ozempic and Wegovy are losing significant weight, and the fashion industry is taking notice. Body size changes on these medications are real, rapid, and worth planning for. Here's what patients need to know about managing a shifting wardrobe and body image during GLP-1 treatment.
GLP-1 medications like semaglutide were designed for blood sugar and weight management, but researchers are now exploring their unexpected effects on addictive behaviors, including gambling. Early findings suggest these drugs may dampen reward-seeking in the brain. Here is what the current evidence actually shows and what it means for patients.
A recent observational study suggests that GLP-1 medications like Wegovy and Mounjaro may help curb cancer spread in people with obesity. While the research is early and not yet definitive, the findings add to a growing body of evidence about benefits beyond weight loss. Here's what patients need to know.
NIH researchers have uncovered new details about how GLP-1 receptor agonists work inside neurons to drive weight loss, opening a potential path toward more effective future therapies. The findings, published in May 2025, shed light on brain-level mechanisms that were previously poorly understood. Here is what the research means for people currently taking or considering GLP-1 medications.
The European Medicines Agency has recommended approving an oral form of semaglutide (Wegovy) for weight management. This is a significant step toward a pill-based GLP-1 option that could change how patients access and experience weight loss treatment.
Insurance co-pays for GLP-1 weight loss medications like Wegovy and Zepbound are climbing, and some plans are dropping coverage entirely. This guide breaks down what's changing, why it's happening, and what practical steps you can take to keep your costs manageable.
Australia has revealed a striking number of Ozempic users, reflecting a global pattern of surging GLP-1 medication demand. This article breaks down what that growth means for patients considering semaglutide, how supply and costs are affected, and what questions to ask your provider before starting.
